



## A Facile Synthesis of Face'd' Azaquinazolino Annulated Analogues of Benzazepinones Through the Corresponding Enol Ether Derivative

<b>Aditi</b>	Department of Chemistry, Banasthali University, Banasthali, Raj. (INDIA)
<b>Singh Rajendra</b>	Dept.Of Chemical sciences, SJJT University, Jhunjhunu, Rajasthan
<b>YadavYogita</b>	Department of Chemistry, Banasthali University, Banasthali, Raj. (INDIA)

### ABSTRACT

protocol to the synthesis of face 'd' azaquinazolino annulated analogues of benzazepinones 5-8 has been developed by reacting compound 2 with ethyl formate in presence of a base to give the corresponding enol ether derivative 3 which underwent cyclocondensation first with malononitrile, in presence of ammonium acetate to give 4 followed by the reaction of the later with urea, thiourea, ethyl glycinate dithioacetal and 2-chloro-3-amino pyridine to afford the corresponding azaquinazolino annulated analogues 5-8 in acceptable yields. 2 resulted from the acylation of p-fluoro aniline 1 with succinyl chloride followed by cyclocondensation of the later with PPA.

### KEYWORDS

Benzazepinone-2,5-dione, enol ether, Friedel-Craft cyclocondensation with PPA

### Introduction

Substituted azaquinazolines are useful antiviral agents, in particular against cytomegaloviruses<sup>1-3</sup>. Several 1,6-naphthyridine or 8-azaquinazoline derivatives have been found to be useful in the treatment of aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke<sup>4</sup>. Azaquinazoline EFGR (epidermal growth factor receptor) has entered into clinical trials for the treatment of cancer, demonstrating the competitive nature of this area<sup>5</sup>. This discovery has stimulated a renewed interest in these molecules from yet another perspective. The biological potential of azaquinazoline nucleus prompted us to focus research on the synthesis and study of biological properties of newer series of heteroring annulated products containing this ring.

In view of the impressive pharmacological properties exhibited by this nucleus it was thought that, it could be worthwhile to incorporate the azaquinazoline ring to the benzazepinone nucleus to verify the assumption that incorporation of the pharmacophores which have previous history of being biologically active, could produce an additive effect on the overall potency in the parent molecule. Herein, in this communication we describe the preliminary results of our synthetic endeavour projected in this direction.



### Related work

Melting points were determined in open glass capillaries and are uncorrected. The purity of the compounds was checked by TLC on silica gel (G) plates. IR spectra were recorded on CE (Schimatzu) FTIR-9050 S. <sup>1</sup>H-NMR spectra and <sup>13</sup>C NMR spectra were recorded on Sea 400 (Bruker) using CDCl<sub>3</sub> as solvent and TMS as an internal reference. Chemical shift are expressed in δ ppm. Mass spectra were recorded on Bosch Tech. X.

### Experimental section

#### Synthesis of 7-fluoro-3,4-dihydro-1H-benzo[b]azepin-2,5-dione (2)

p-Fluoroaniline (**1**) (3.60ml, 0.03 mol) was mixed with succinyl chloride (4.92g, 0.03 mol) in dry pyridine (20.0 ml) and the mixture was refluxed for 15 min. Cold reaction mixture was poured slowly with stirring to 150-200ml ice cold water. The solid which settled was filtered, washed with cold water, recrystallized from methanol and water. PPA (25g) was mixed to 3.21 g (0.01 mol) of it and heated at 150-160°C for 4h (the progress of the reaction was monitored by TLC). The reaction mixture was cooled to 20°C and a concentrated aqueous solution of Na<sub>2</sub>CO<sub>3</sub> was added to make it alkaline. The product was extracted with ethyl acetate (3x10 ml). The extract was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum. The residue was purified by column chromatography on silica gel with CHCl<sub>3</sub> as an eluent to give **2** (2.85g, yield :79%); m.p.: 158-160 °C; IR (KBr) cm<sup>-1</sup>: 3240(N-H str.), 2990 (C-H str.), 2900, 1400 (-CH<sub>2</sub> next to C=O), 1712, 1704 (C=O), 1535 (C=Cstr.); <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.0 (1H, s, NH), 7.26-7.78 (3H, m, Ar-H), 3.49 (4H, s, (CH<sub>2</sub>)<sub>2</sub>); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [157.55 (CF), 120.24 (CH), 113.54 (CH), 112.44 (CH)], Ar-C [134.44 (C), 115.25 (C, azepinone), 27.6, 34.4 [(CH<sub>2</sub>)<sub>2</sub> azepinone)], 176.75 (C of amide), 183.49 (C of carbonyl); MS: m/z 193.17(M<sup>+</sup>); Anal. calcd. / found for C<sub>10</sub>H<sub>8</sub>FNO<sub>2</sub>: C, 62.18 / 62.35; H, 4.17/4.11; N, 7.25/7.48.

#### Preparation of 4 - (ethoxymethylene) -7- fluoro -3,4 - dihydro -1H- benzo [b]azepin-2,5-dione (3)

To a solution of 10% sodium ethoxide (1.09g ,0.016 mol) in dry benzene (50ml) at 0°C, a solution of ethyl formate (1.18g, 0.016 mol) in dry benzene (25 ml) was added. To this mixture, 7-fluoro-3,4-dihydro-1H-benzo[b]azepin-2,5-dione (**2**) (3.25g, 0.016 mol) in dry benzene (25ml) was added. The mix-

ture was stirred for 4 h at room temperature and allowed to stand overnight. It was then diluted with cold water, acidified with dil. HCl and extracted with ether. The solvent was evaporated and the resultant compound was recrystallized with ethanol to give **3** (2.85g, yield: 88%); m.p. : 298-300°C; IR (KBr) cm<sup>-1</sup>: 3240(N-H str.), 3000(C-H str.), 2980, 1400 (-CH<sub>2</sub> next to C=O), 1680, 1700(C=O), 1590(C=C str.), 1250(C-O str. of ether); <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.0 (1H, s, NH), 7.457.98(3H, m, Ar-H), 7.12(1H, s, CH), 4.49(2H, q, CH<sub>2</sub> of ethyl), 2.90 (2H, s, CH<sub>2</sub>), 1.21(3H, t, CH<sub>3</sub> of ethyl); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [164.56(CF), 121.55(CH), 113.14 (CH), 112.16(CH)], 168.19 (amide carbon), 177.67(carbonyl carbon), 36.14 (CH<sub>2</sub> of azepinone), Ar-C [136.84(C), 128.32(C), 121.62(C), azepinone], 162.64 (=CHOEt), 71.55, 15.34 (C of ethyl); MS, m/z: 249.02 (M<sup>+</sup> 80.0%), 208.04 (100.0%), 152.29(9.6%); Anal. calcd. / found for C<sub>13</sub>H<sub>12</sub>FNO<sub>3</sub>: C, 62.65 / 62.40; H, 4.85/4.89; N, 5.62/5.33.

#### Preparation of 2-amino-10-fluoro-6-oxo-6,7-dihydro-5H-benzo[b]pyrido [2,3-d]-azepin-3-carbonitrile (4)

A mixture of 4-(ethoxymethylene)-7-fluoro-3,4-dihydro-1H-benzo [b]azepin-2,5-dione (**3**) (2.81g, 0.01mol), malononitrile (0.66g, 0.01mol) and ammonium acetate (0.6g, 0.08mol) dissolved in ethanol (25ml) was heated under reflux for 8h. The contents were poured into crushed ice, filtered and recrystallized with ethanol to give **4** (2.12g, yield: 75%); m.p.: 220-222°C; IR (KBr) cm<sup>-1</sup>: 3370(NH<sub>2</sub>), 3210(N-H str.), 3010(C-H str.), 2975, 1400 (CH<sub>2</sub> next to C=O), 2100(CN), 1680 (C=O), 1596(C=N), 1580(C=C str.); <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.24(1H, s, CH of pyridine ring), 8.01(1H, s, NH), 7.24-7.88(3H, m, Ar-H), 7.15(2H, s, NH<sub>2</sub>), 3.70(2H, s, CH<sub>2</sub>); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [163.78(CF), 123.74(CH), 116.66 (CH), 114.55(CH)], 176.78 (amide carbon), 44.22 (CH<sub>2</sub> azepinone), Ar-C [168.24(C), 134.27(C), 129.23 (C), 122.24(C), azepinone], 139.76 (CH, pyridine), 163.24(-CNH<sub>2</sub>), 102.09(-CCN), 122.39(C of CN); MS, m/z: 268.15 (M<sup>+</sup> 65.0%), 260.07 (11.5%), 241.03(100.0%), 141.12(1.5%); Anal. calcd. / found for C<sub>14</sub>H<sub>9</sub>FN<sub>4</sub>O: C, 62.68 / 62.89; H, 3.38/3.31; N, 20.89/20.48.

#### Preparation of 9-amino-2-fluoro-5H-benzo[b]pyrimido-5[4',5':6]-pyrido [2,3-d]azepin-6,11(7H,12H)-dione (5)

A mixture of 2-amino-10-fluoro-6-oxo-6,7-dihydro-5H-benzo[b]pyrido [2,3-d]azepin-3-carbonitrile (**4**) (2.10g, 0.008mol) and urea (0.48g, 0.008 mol) was heated in an oil bath at 120°C for 4h with constant stirring. The temperature was raised to 180°C and finally the mixture was heated at 220°C for 4h. On cooling, the product solidified, which was recrystallised from DMF-EtOH mixture to give **5** (1.54g, yield: 73%); m.p.: 248-252°C; IR (KBr) cm<sup>-1</sup>: 3370(NH<sub>2</sub>), 3210(N-H str.), 3000(C-H str.), 2970, 1400(CH<sub>2</sub> next to C=O), 1600(C=O), 1540(C=C str.), 1530(C=N); <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.38 (1H, s, CH of pyridine ring), 8.13(1H, s, NH), 7.64-8.64(3H, m, Ar-H), 7.47(1H, s, NH of pyrimidine ring), 7.17 (2H, s, NH<sub>2</sub>), 3.70(2H, s, CH<sub>2</sub>); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [163.88(CF), 123.16(CH), 114.53(CH), 114.44(CH)], 172.68(C of amide), Ar-C [167.50(C), 152.46(C), 130.57 (C), 113.13 (C), azepinone], 39.16(CH<sub>2</sub> azepinone), Ar-C [168.01(C), 143.17(CH), 100.38 (C), pyridine], 183.48(-CNH<sub>2</sub>), 170.43(C of carbonyl); MS, m/z: 311.27 (M<sup>+</sup> 45%), 261.22% (100.0%), 308.36(15%), 176.02(35%), 110.75(20%); Anal. calcd. / found for C<sub>15</sub>H<sub>10</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>: C, 57.88 / 57.65; H, 3.24/3.20; N, 22.50/22.68.

#### Preparation of 9-amino-2-fluoro-11-thioxo-11,12-dihydro-5H-benzof[b] pyrimido[5',4':5,6]-pyrido-[2,3-d]azepin-6,11(7H)-one (6)

A mixture of 2-amino-10-fluoro-6-oxo-6,7-dihydro-5H-benzo[b]pyrido [2,3-d]azepin-3-carbonitrile (**5**) (2.10g, 0.008 mol) and thiourea (0.60g, 0.008 mol) was heated in an oil bath at 120°C for 4h with constant stirring. The temperature was raised to 180°C and finally the mixture was heated at 220°C for 4h. On cooling the product solidified, which was recrystallised from DMF-EtOH mixture to give **6** (1.64g, yield: 78%); m.p.: 246-248°C; IR (KBr) cm<sup>-1</sup>: 3350(NH<sub>2</sub>), 3230(N-H str.), 3010(C-H str.), 2975, 1400(CH<sub>2</sub> next to C=O), 1620 (C=O), 1570(C=N), 1530(C=C str.), 780(C=S);

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.36 (1H, s, CH of pyridine ring), 8.1(1H, s, NH), 7.68-8.69(3H, m, Ar-H), 7.15(2H, s, NH<sub>2</sub>), 4.0(1H, s, NH of pyrimidine ring), 3.70(2H, s, CH<sub>2</sub>); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [163.78(C), 123.22(C), 114.58 (C), 114.48(C)], 172.16(C of amide), 39.18(CH<sub>2</sub> azepinone), Ar-C [167.55(C), 152.48(C), 130.57(C), 113.13 (C), azepinone], Ar-C [167.22(C), 143.24(CH), 100.34 (C), pyridine], 180.4(C of C=S), 182.44(-CNH<sub>2</sub>); MS, m/z: 327.18 (M<sup>+</sup> 70%), 272.23(100%), 318.34(15%), 180.04 (32.5%); Anal. calcd. / found for C<sub>15</sub>H<sub>11</sub>FN<sub>5</sub>O<sub>2</sub>S: C, 55.04/55.25; H, 3.08/3.02; N, 21.39/21.63; S, 9.80/9.57.

#### Preparation of 9-fluoro-5(methylthio)-12,14-dihydro-2H-benzo [b] imidazo [1'', 2'':1',6']-pyrimido-[5',4':5,6]-pyrido[2,3-d]azepin-2,13 (3H)-dione (7)

A mixture of 2-amino-10-fluoro-6-oxo-6,7-dihydro-5H-benzo[b]pyrido [2,3-d]azepin-3-carbonitrile (**5**) (2.10g, 0.008 mol) and ethylglycinate dithioacetal (1.66 g, 0.008 mol) in glacial acetic acid (20 ml) was heated under reflux for 4 h. The reaction mixture was allowed to cool, poured on ice and neutralized with sodium carbonate. The precipitate was filtered off and recrystallized with ethanol to give **7** (1.5g, yield: 71%); m.p.: 390-392°C; IR (KBr) cm<sup>-1</sup>: 3240(N-H str.), 3000(C-H str.), 2985, 1400(CH<sub>2</sub> next to C=O), 1610, 1800(C=O), 1570(C=N str.), 1535(C=C str.), 680(C-S str.); <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.35(1H, s, CH of pyridine ring), 8.03(1H, s, NH), 7.62-8.58(3H, m, Ar-H), 3.76(2H, s, CH<sub>2</sub> of pyrrole ring), 3.70(2H, s, CH<sub>2</sub>), 2.55(3H, s, CH<sub>3</sub>); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [163.78(CF), 123.22(CH), 115.55 (CH), 115.42(CH)], 171.56(C of amide), Ar-C [167.47(C), 152.52(C), 129.67(C), 114.15(C) azepinone], 44.24(CH<sub>2</sub> azepinone), Ar-C [167.58(C), 141.27 (CH), 100.38 (C) pyridine], Ar-C [168.34(C), 155.39(C), pyrimidine], 59.39(CH<sub>2</sub> pyrrole), 170.83(C of carbonyl), 14.1(1C of CH<sub>3</sub>); MS, m/z: 381.15 (M<sup>+</sup> 85.0%), 313.07(100.0%), 246.42(15.5%), 183.08(21.8%); Anal. calcd. / found for C<sub>16</sub>H<sub>11</sub>FN<sub>5</sub>O<sub>2</sub>S<sub>2</sub>: C, 59.69/59.43; H, 3.17/3.11; N, 18.36/18.14; S, 8.41/8.62.

#### Preparation of 9-amino-2-fluoro-7,15-dihydrobenzo[6',7']azepino [4',5':5,6] pyrido[2,3-e] pyrido[3,2-b] [1,4]diazepin-6(5H)-one(8)

2-Amino-10-fluoro-6-oxo-6,7-dihydro-5H-benzo[b]pyrido [2,3-d] azepin-3-carbonitrile (**5**) (2.10g, 0.008 mol) was fused with 2-chloro-3-amino-pyridine (1.02 g, 0.01 mol) to form a homogenous solution. Then anhydrous AlCl<sub>3</sub> (0.008 mol) was added, and the reaction mixture was heated at 170-180°C for 20 min. 10% aq. HCl solution was added, and mixture was heated for 5 min. The resulting solution was filtered while hot into a conical flask containing 10% NaOH solution. The precipitates that formed was collected by filtration under suction, washed with water until the filtrate was neutral, and left to dry at room temperature overnight to give **8** (1.42g, yield: 68%); m.p.: 149-151°C; IR (KBr) cm<sup>-1</sup>: 3360(NH<sub>2</sub>), 3230(N-H str.), 3010(C-H), 2975, 1400(CH<sub>2</sub> next to C=O), 1680 (C=O), 1575(C=N), 1530(C=C str.); <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: 8.34(1H, s, CH of pyridine ring), 8.01(1H, s, NH), 7.54-8.54(3H, m, Ar-H), 7.62-8.77(3H, m, CH of pyridine ring), 7.13(2H, s, NH<sub>2</sub> of diazepine), 4.0(1H, s, NH of diazepine), 3.70(2H, s, CH<sub>2</sub>); <sup>13</sup>C-NMR (400MHz, CDCl<sub>3</sub>) δ ppm: Ar-C [163.46(CF), 124.32(CH), 115.51(CH), 114.46(CH)], 172.45(C of amide), 44.22 (CH<sub>2</sub> azepinone), Ar-C [168.2(C), 134.47(C), 129.34(C), 122.22 (C), azepinone], Ar-C [167.58(C), 141.27(CH), 100.38(C), pyridine], 164.0(-CNH<sub>2</sub>), Ar-C [149.7(C), 108.3(C), diazepine], Ar-C [146.54(CH), 132.45(CH), 113.43 (CH), pyridine]; MS, m/z: 360.12 (M<sup>+</sup> 70.0%), 311.12(100.0%), 226.11(22.2%), 160.32(15.2%); Anal. calcd. / found for C<sub>19</sub>H<sub>13</sub>F<sub>2</sub>N<sub>6</sub>O: C, 63.33 / 63.57; H, 3.64/3.60; N, 23.32/23.11.

#### Results

The synthesis of compounds **5-8** wherein one can easily discern the presence of a variety of bioactive pharmacophores in their molecules was conceived in the present communication from enol ether following the strategy shown in Scheme-1. The synthesis consisted of reacting compound **2** with ethyl formate in presence of a base to give **3** which underwent

reaction with malononitrile and ammonium acetate formed the corresponding amino benzonitrile derivative **4**, which on treatment with urea<sup>6</sup>, thiourea<sup>6</sup>, ethyl glycinate dithioacetal<sup>7-8</sup> and 2-chloro-3-amino pyridine<sup>9,10</sup> generated the azaquinazoline annulated analogues of benzazepinone **5-8**.

### Conclusion

In summary, a facile protocol has been developed to provide the annulation of face 'd' of the benzazepinone nucleus with azaquinazolone ring by exploring the unprecedented potential of enol ether in this venture.

### References

1. T. Wunberg, J. Baumeister, M. Jeske, F. Submeier, H. Zimmermann, K. Henninger and D. Lang, Substituted azaquinazolines having an antiviral action, *Pat. U.S. 7662822 B2*, **2010**.
2. D. Bevec, P. Hanbenberger, D. Schubart, M. Stein and Gerlach, Cellular kinase inhibitors involved in cytomegalovirus infection and their inhibitors, *EP 1201765 A3*, **2002**.
3. T. Wunberg, J. Baumeister, M. Jeske, F. Submeier, H. Zimmermann, K. Henninger and D. Lang, Substituted azaquinazolines having an antiviral action, *Pat. U.S. 8198282*, **2012**.
4. L. Barfacker, R. Grosser, P. Kolkhef, A. Nitsche and K.H. Schlemmer, New 1,6-naphthyridine or 8-azaquinazoline derivatives useful for treating aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke, *DE 102007009494A1*, **2008**.
5. G.W. Rewcastle, W.A. Denny and H.D.H. Showalter, Synthesis of 4-(phenylamino)-pyrimidine derivatives as ATP-competitive protein kinase inhibitors with potential for cancer chemotherapy, *Curr.Org.Chem.*, **2000**, 4(7), 679-706.
6. M.R. Patel, J.D. Akbari and D.H. Purohit, Synthesis and evaluation of pharmacological activity of some new amino pyrimidine and thiopyrimidine derivatives, *J. Ind.Chem.Soc.*, **2007**, 84(11), 1169.
7. A. Lauria, M. Bruno, P. Barraja, A. Montalbano, G. Cirrincione, G. Datto and A.M. Almerico, Annelated pyrrolo-pyrimidines from amino-cyanopyrroles and BMMA as leads for new DNA-interactive ring systems, *Bioorg. Med. Chem.*, **2005**, 13, 1545.
8. N. M.Nahas, Synthesis of condensed pyrimidines in one-pot reaction from pyranoquinolines and BMMA, *Heterocycl.Commun.*, **2008**, 14, 1-2.
9. K.M. El-Shaieb, H. Hopf and P.G. Jones, A general synthesis of 4-aryl amino quinazoline - 2-carbonitriles, *Z.Naturforsch.*, **2009**, 64b, 858-864.
10. R. Patel, P. Kumari and K. Chikhaliya, Novel s-Triazinyl piperazines: Design, synthesis, characterization and anti-microbial activity, *Arch. Appl. Sci.Res.*, **2010**, 2(6), 232-240.